A Simple Blood Test to Predict Thyroid Cancer Recurrence
A new study in Clinical Endocrinology suggests a straightforward blood marker could improve risk stratification for patients with intermediate-risk differentiated thyroid carcinoma (DTC). Researchers found that a high monocyte-to-lymphocyte ratio (MLR), measured from a blood sample taken before radioactive iodine (RAI) treatment, was an independent predictor of earlier and more frequent cancer recurrence. In a cohort of 282 patients followed for a median of over seven years, an MLR above 0.188 was significantly associated with shorter recurrence-free survival, outperforming other inflammatory and nutritional indices. This finding highlights the potential role of the host’s systemic inflammatory response in cancer prognosis.
Why it might matter to you: For clinicians managing thyroid disorders, particularly in reproductive-aged women where thyroid cancer is prevalent, this biomarker offers a practical tool for personalizing post-treatment surveillance. Integrating the MLR into existing risk models could help identify which intermediate-risk patients require more intensive monitoring, optimizing resource allocation and potentially catching recurrences earlier. This approach aligns with a broader trend in oncology and endocrinology towards leveraging host-factors for refined prognostic stratification.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
